Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Glaxo Zyban/Wellbutrin DTC Accounts Move To Grey Advertising

Executive Summary

The award of Glaxo's bupropion franchise to Grey Advertising consolidates six of the firm's nine DTC-advertised products into one agency.

You may also be interested in...



P&G/Aventis Actonel Joins Fosamax In Non-Hormonal Osteoporosis Market

Procter & Gamble's Actonel enters the osteoporosis market as the second bisphosphonate, behind Merck's Fosamax.

P&G/Aventis Actonel Joins Fosamax In Non-Hormonal Osteoporosis Market

Procter & Gamble's Actonel enters the osteoporosis market as the second bisphosphonate, behind Merck's Fosamax.

AstraZeneca Nexium NDA Includes "On-Demand" Dosing

AstraZeneca's NDA for the Prilosec follow-on product Nexium includes an indication for "on demand" maintenance treatment for gastroesophageal reflux disease.

Related Content

UsernamePublicRestriction

Register

LL043624

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel